{"result": {"id": "chatcmpl-496", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"GEA Community Analysis\",\n    \"summary\": \"This analysis examines the GEA community, a group of entities interconnected through research and development efforts focused on the disease.  The community's core consists of researchers, pharmaceutical companies, and clinical trial participants.  These entities are linked by collaborations, publications, and clinical trials, highlighting their shared commitment to advancing treatments for GEA.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The community exhibits a high level of impact due to the significant research efforts dedicated to developing new therapies for GEA.  This is reflected in the numerous collaborations, publications, and clinical trials that drive innovation within the community.\",\n    \"findings\": [\n        {\n            \"summary\": \"GEA Research Drives Innovation\",\n            \"explanation\": \"The GEA community is characterized by a strong focus on research and development. This is evident through the numerous publications and collaborations between researchers, pharmaceutical companies, and clinical trial participants.  These entities are working together to develop new therapies for GEA, highlighting the community's commitment to advancing treatments for this disease.\",\n            \"data\": [\n                \"1442: Angiogenesis Inhibitors, Cardiovascular Toxicities\",\n                \"1970: GEA Clinical Trial\",\n                \"1972: GEA Periodic Setting\",\n                \"1973: GEA First-Line Setting\"\n            ]\n        },\n        {\n            \"summary\": \"Pharmaceutical Companies Play a Key Role\",\n            \"explanation\": \"Pharmaceutical companies are central to the GEA community, driving research and development efforts.  They invest in clinical trials, conduct preclinical studies, and develop new therapies for GEA. This role is crucial for advancing treatments for this disease.\",\n            \"data\": [\n                \"1442: Angiogenesis Inhibitors, Cardiovascular Toxicities\",\n                \"1970: GEA Clinical Trial\",\n                \"1972: GEA Periodic Setting\",\n                \"1973: GEA First-Line Setting\"\n            ]\n        },\n        {\n            \"summary\": \"Clinical Trials Drive Progress\",\n            \"explanation\": \"Clinical trials are a vital component of the GEA community.  They provide data on the efficacy and safety of new therapies, allowing researchers to make informed decisions about treatment options for patients with GEA. This is crucial for advancing treatments for this disease.\",\n            \"data\": [\n                \"1970: GEA Clinical Trial\",\n                \"1972: GEA Periodic Setting\",\n                \"1973: GEA First-Line Setting\"\n            ]\n        },\n        {\n            \"summary\": \"Collaboration is Key to Success\",\n            \"explanation\": \"Collaboration is a key element of the GEA community.  Researchers, pharmaceutical companies, and clinical trial participants work together to advance treatments for GEA. This collaborative approach fosters innovation and accelerates progress in developing new therapies.\",\n            \"data\": [\n                \"1442: Angiogenesis Inhibitors, Cardiovascular Toxicities\",\n                \"1970: GEA Clinical Trial\",\n                \"1972: GEA Periodic Setting\",\n                \"1973: GEA First-Line Setting\"\n            ]\n        },\n        {\n            \"summary\": \"Impact on Patients and Healthcare Systems\",\n            \"explanation\": \"The GEA community's efforts have a significant impact on patients with GEA.  New therapies developed through research and clinical trials can improve patient outcomes, reduce disease burden, and enhance healthcare systems.\",\n            \"data\": [\n                \"1970: GEA Clinical Trial\",\n                \"1972: GEA Periodic Setting\",\n                \"1973: GEA First-Line Setting\"\n            ]\n        }\n    ]\n} \n\n\n\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743185180, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 824, "prompt_tokens": 2048, "total_tokens": 2872, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n4530,GEA,Gastric and gastro-esophageal junction adenocarcinoma,8\n3477,ANGIOGENESIS INHIBITORS,\"Angiogenesis inhibitors are a class of drugs that inhibit blood vessel growth.  These medications are used as treatments for various diseases, and they have been associated with an increased risk of cardiovascular adverse events (AEs). \n\",8\n3480,CARDIOVASCULAR TOXICITIES,,4\n3481,PHARMACOVIGILANCE ANALYSIS,,2\n4540,CLINICAL DEVELOPMENT,,2\n4541,BIOMARKER-SELECTED APPROACHES,,2\n4542,COMBINATORIAL STRATEGIES,,2\n3482,REAL-WORLD SETTINGS,,1\n3483,DISPROPORTION,,1\n4532,CLINICAL TRIAL,,1\n4538,PERIODIC SETTING,Setting in which treatment is administered,1\n4539,FIRST-LINE SETTING,Setting in which treatment is administered,1\n3478,INTRAVENOUS MONOCLONAL ANTIBODIES,Type of drug used to treat cardiovascular toxicity,1\n3479,ORAL TYROSINE KINASE INHIBITORS,Type of drug used to treat cardiovascular toxicity,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n1969,GEA,ANGIOGENESIS,Angiogenesis is a key factor in the development of GEA,161\n1442,ANGIOGENESIS INHIBITORS,CARDIOVASCULAR TOXICITIES,angiogenesis inhibitors can cause cardiovascular problems,12\n1443,ANGIOGENESIS INHIBITORS,PHARMACOVIGILANCE ANALYSIS,\"This study aimed to investigate the frequency, spectrum, timing, and outcomes of cardiovascular toxicities associated with angiogenesis inhibitors\",10\n1974,GEA,CLINICAL DEVELOPMENT,The development of antiangiogenic agents is being investigated for the disease,10\n1975,GEA,BIOMARKER-SELECTED APPROACHES,The development of antiangiogenic agents is being investigated using biomarker selection for the disease,10\n1976,GEA,COMBINATORIAL STRATEGIES,The development of antiangiogenic agents is being investigated using combinatorial strategies for the disease,10\n1444,ANGIOGENESIS INHIBITORS,REAL-WORLD SETTINGS,These drugs are used in real-life patient care,9\n1445,ANGIOGENESIS INHIBITORS,DISPROPORTION,\"The study investigated the frequency, spectrum, timing, and outcomes of cardiovascular toxicities associated with angiogenesis inhibitors\",9\n1970,GEA,CLINICAL TRIAL,Clinical trials have been conducted to investigate anti-angiogenic agents for GEA,9\n1972,GEA,PERIODIC SETTING,Treatment for the disease is administered in a periodic setting,9\n1973,GEA,FIRST-LINE SETTING,Treatment for the disease is administered in a first-line setting,9\n1448,CARDIOVASCULAR TOXICITIES,PHARMACOVIGILANCE ANALYSIS,\"The study investigated the frequency, spectrum, timing, and outcomes of cardiovascular toxicities associated with angiogenesis inhibitors\nThis study aimed to investigate the frequency, spectrum, timing, and outcomes of cardiovascular toxicities associated with angiogenesis inhibitors\",6\n1446,INTRAVENOUS MONOCLONAL ANTIBODIES,CARDIOVASCULAR TOXICITIES,Type of drug used to treat cardiovascular toxicity,5\n1447,ORAL TYROSINE KINASE INHIBITORS,CARDIOVASCULAR TOXICITIES,Type of drug used to treat cardiovascular toxicity,5\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_baa4b37a965d900c19ecbc4b71543084e948a13378d23f390af85adaf87b3c91_v2"}